Company profile: Aethon
1.1 - Company Overview
Company description
- Provider of automated hospital delivery and asset management solutions, including TUG®, an automated robotic delivery system transporting scheduled and on-demand deliveries across ancillary, support and patient care units. Offers autonomous mobile robots for material handling in hospitals, manufacturing and hotels, with secured delivery, cart handling, and payloads up to 1,400 lb.
Products and services
- TUG T3XL: An industrial-grade autonomous mobile robot with 1,400 lb payload capacity, omnidirectional locomotion, and automatic dropoff and pickup for heavy material transport
- TUG T3: A mid-capacity autonomous delivery robot featuring 1,000 lb payload capacity, omnidirectional movement, and automatic cart handling for reliable transport of supplies within facilities
- TUG: A hospital-grade Automated Robotic Delivery (ARD) system transporting scheduled and on-demand deliveries across ancillary, support, and patient care units, enabling cost-effective asset tracking infrastructure in hospitals, manufacturing, and hotels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aethon
bit.bio
HQ: United Kingdom
Website
- Description: Provider of proprietary cell programming technology and human iPSC-derived cell products for research and drug discovery. Bit.bio develops opti-ox to convert iPSCs into mature, functional human cells and offers ioCells for consistent, scalable supply. The company applies computational principles to biology to code cells for health, including collaboration with The Michael J. Fox Foundation on Parkinson’s research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full bit.bio company profile →
Lucy Therapeutics
HQ: United States
Website
- Description: Provider of mitochondrial-based small molecule therapies targeting mitochondrial dysfunction to treat complex diseases with a focus on neurological disorders; diagnostic biomarkers for disease diagnosis and progression monitoring; lead programs in Parkinson's disease and Rett syndrome; and early discovery efforts for undisclosed targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lucy Therapeutics company profile →
Stratec
HQ: Germany
Website
- Description: Provider of lab automation solutions and automated analyzer systems for IVD, clinical diagnostics, biotechnology, and life science sectors, offering laboratory data management and molecular diagnostic sample preparation and stabilization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stratec company profile →
Ion Torrent
HQ: United States
Website
- Description: Provider of sequencing technology that enables a direct connection between chemical and digital information; the first commercial PostLight sequencing technology that doesn't use light. Ion Torrent is a wholly-owned subsidiary of Life Technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ion Torrent company profile →
Delphi Genetics
HQ: Belgium
Website
- Description: Provider of plasmid DNA and genetic engineering services, developing customized GMP plasmid DNA manufacturing solutions to support viral and non-viral gene therapy programs, based on unique technologies including patented STABY® technology without antibiotic resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delphi Genetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aethon
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aethon
2.2 - Growth funds investing in similar companies to Aethon
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aethon
4.2 - Public trading comparable groups for Aethon
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →